Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations.
Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB test at a rate of approximately 60 Euros per test.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT. TB test, which is used to test for tuberculosis infection. The T-SPOT. TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT. CMV test and the T-SPOT. PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
Tel: +1 (443) 213-0501
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Raven Indusries Releases CR12(TM) Field Computer18.6.2018 16:49 | Pressmeddelande
12-Inch Display With Field Planning Features Helps Farmers Save Time and Increase Efficiencies MIDDENMEER, The Netherlands, June 18, 2018 (GLOBE NEWSWIRE) -- Raven Industries (NASDAQ:RAVN) announced today the release of a new, larger field computer: the CR12(TM). Utilizing the same powerful functionality as the CR7(TM) field computer, the CR12 offers an extensive field planning feature for increased efficiencies. Built with a durable magnesium waterproof housing and a full glass capacitive touchscreen with high brightness, the CR12 also boasts a wider, 12.1-inch display. The CR12 joins the CR7 as the latest field computer in the CRX display family. This powerful operating system features easy job set-up, fewer touches and greater efficiencies - empowering the user with extraordinary data management capabilities. A simple widget concept, easily accessible settings, and ISO Universal Terminal and Task Controller capabilities make this mighty unit an affordable, plug-and-play system. Like
FPGA programming solution goes live at AEE 2018 in latest version of SLX18.6.2018 15:00 | Pressmeddelande
Silexica / FPGA programming solution goes live at AEE 2018 in latest version of SLX . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Industry-first solution fully explores the design space to optimize hardware/software partitioning SLX automatically inserts pragmas and rewrites code to make it High-Level Synthesis (HLS) ready Solution designed in collaboration with customers including Ricoh SAN JOSE, Calif. and COLOGNE, Germany, June 18, 2018 (GLOBE NEWSWIRE) -- Silexica will launch a new solution within SLX to support the increasing use of FPGAs for embedded computing tasks such as sensor fusion and deep learning. It has been developed in partnership with Ricoh and other customers who will use the solution for industrial automation and defense projects. The technology will be presented at Silexica's first appearance one of the world's biggest avionics exhibitions - AEE held in Munich from June 19-20. The
Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research18.6.2018 14:00 | Pressmeddelande
Pressmeddelande 18 juni 2018 Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research Immunicum AB (publ; IMMU.ST) offentliggjorde i dag online-publiceringen av en översiktsartikel av den senaste tidens utveckling inom immunonkologiforskning, med särskilt fokus på tidigare publicerade data som stöder värdet av bolagets ledande program, ilixadencel. Artikeln, med titeln "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration" publicerades on-line i Pharmaceutical Research , American Association of Pharmaceutical Scientists officiella tidskrift. Artikeln finns via följande länk https://link.springer.com/article/10.1007/s11095-018-2438-x - Det är en ära för vårt forsknings- och utvecklingsteam på Immunicum att bli erbjudna att skriva denna omfattande översikt som tar upp ilixadencels verkningsmekanism mot bakrund av de senaste upptäckterna gällande immunaktivering mot cancer. Våra preklin
Goldman Sachs and Cisco to Host Tech Talk on Data Center Networking18.6.2018 14:00 | Pressmeddelande
SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Cisco will host a conference call with Goldman Sachs and Cisco's Ish Limkakeng, SVP, Product Management, Data Center Networking Group. The discussion will focus on Cisco's data center networking strategy, comprehensive portfolio, and its competitive advantage as customers seek highly secure and differentiated offerings. Interested parties can find more information on Cisco's Investor Relations website at https://investor.cisco.com. No new financial information will be discussed on this conference call. Date: Thursday, June 21, 2018 Time: 8:30 am PT / 11:30 am ET Speaker: Ish Limkakeng, SVP, Product Management, Data Center Networking Group Moderator: Goldman Sachs' Rod Hall, Managing Director Participant Dial in: Toll Free: 877-208-2954 International Number: 973-528-0056 Passcode: 201872 Replay Information (available until July 5, 2018): Toll Free: 800-332-6854 International Number: 973-528-0005 Passcode: 201872 This event will be webc
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research18.6.2018 14:00 | Pressmeddelande
Press Release 18 June 2018 Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research Immunicum AB (publ; IMMU.ST) announced today the online publication of a review article providing an overview of recent developments in immuno-oncology research, specifically focusing on previously published data supporting the value of its lead program, ilixadencel. The article, titled "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration", was published in Pharmaceutical Research , the official journal of the American Association of Pharmaceutical Scientists. The article can be accessed via the following link https://link.springer.com/article/10.1007/s11095-018-2438-x "It is an honor for our research and development team at Immunicum to be invited to write this in-depth review article covering ilixadencel's mode of action in context of the most recent discoveries in anti-cancer immune activation," comme
DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23 | Pressmeddelande
Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum